Alps Advisors Inc. decreased its position in Cambrex Corp. (NYSE:CBM) by 6.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,844 shares of the company’s stock after selling 720 shares during the period. Alps Advisors Inc.’s holdings in Cambrex Corp. were worth $509,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of CBM. Bayesian Capital Management LP acquired a new position in shares of Cambrex Corp. during the first quarter worth approximately $276,000. Aperio Group LLC raised its position in shares of Cambrex Corp. by 3.0% in the first quarter. Aperio Group LLC now owns 7,576 shares of the company’s stock worth $333,000 after buying an additional 221 shares during the period. Glenmede Trust Co. NA raised its position in shares of Cambrex Corp. by 15.7% in the first quarter. Glenmede Trust Co. NA now owns 11,888 shares of the company’s stock worth $522,000 after buying an additional 1,612 shares during the period. BNP Paribas Arbitrage SA raised its position in shares of Cambrex Corp. by 106.5% in the second quarter. BNP Paribas Arbitrage SA now owns 10,385 shares of the company’s stock worth $537,000 after buying an additional 5,356 shares during the period. Finally, Capstone Asset Management Co. raised its position in shares of Cambrex Corp. by 11.8% in the second quarter. Capstone Asset Management Co. now owns 13,070 shares of the company’s stock worth $676,000 after buying an additional 1,380 shares during the period. Institutional investors own 99.46% of the company’s stock.
Cambrex Corp. (NYSE:CBM) traded up 1.71% during trading on Monday, reaching $45.22. 306,638 shares of the company traded hands. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of 22.86 and a beta of 1.57. The firm’s 50 day moving average price is $45.01 and its 200 day moving average price is $47.80. Cambrex Corp. has a 12-month low of $29.50 and a 12-month high of $59.41.
Cambrex Corp. (NYSE:CBM) last posted its earnings results on Thursday, July 28th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.59 by $0.09. Cambrex Corp. had a net margin of 13.97% and a return on equity of 24.86%. The business had revenue of $118.22 million for the quarter, compared to analysts’ expectations of $114.85 million. During the same period in the prior year, the company posted $0.63 EPS. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. Equities research analysts expect that Cambrex Corp. will post $2.56 earnings per share for the current year.
Separately, Zacks Investment Research lowered shares of Cambrex Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, June 29th.
In other Cambrex Corp. news, Director William B. Korb sold 3,420 shares of the stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $55.00, for a total value of $188,100.00. Following the sale, the director now directly owns 23,982 shares in the company, valued at approximately $1,319,010. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.63% of the stock is currently owned by company insiders.
Cambrex Corp. Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corp. (NYSE:CBM).
Receive News & Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.